Intelligence

Consumer Staples

CV Sciences Reports Third Quarter 2025 Financial Results

Author:
FAQsIR News Desk
Last Updated:
Reading Time
2 min

#Overview of Financial Results

CV Sciences, Inc. has released its financial results for the third quarter of 2025, reporting revenues of $3.3 million. This figure represents a 16% decrease from $3.9 million in the third quarter of 2024 and a slight decline from $3.6 million in the preceding quarter.

#Gross Margin and EBITDA Performance

The company achieved a gross margin of 48.5% in the latest quarter, up from 46.0% in the same quarter of 2024, although it marked a decrease from 50.9% in Q2 2025. Additionally, CV Sciences reported an adjusted EBITDA loss of $118,000 for Q3 2025, compared to a loss of $75,000 in Q3 2024 and a positive adjusted EBITDA of $59,000 in the previous quarter.

#Operational Challenges

The decrease in sales volume was attributed to inventory shortages for key products combined with regulatory challenges in certain states. Overall, unit sales in the third quarter dropped by 16% year-over-year. Despite this, new product launches since January 2023 accounted for 39% of the net revenue generated in this quarter, underscoring the company's ongoing commitment to product development.

#Strategic Direction and Regulatory Engagement

Joseph Dowling, the Chief Executive Officer of CV Sciences, expressed optimism regarding the company’s strategy focused on innovation and potential mergers and acquisitions to bolster revenue. Dowling also addressed recent funding legislation affecting the hemp industry, noting its potential implications and the company’s plan to engage with lawmakers for a favorable regulatory framework.

#Cash Position

At the end of Q3 2025, CV Sciences held a cash balance of $0.4 million, a decrease from $0.5 million observed at the close of 2024. Maintaining sufficient liquidity remains essential as the company pursues new growth opportunities.

#Key Takeaways

  • Third-quarter revenue stood at $3.3 million, a 16% decline year-over-year.
  • Gross margin increased to 48.5%, but the adjusted EBITDA loss was $118,000.
  • Sales decline attributed to inventory shortcomings and regulatory issues.
  • The company launched 38 new products since the start of 2023, contributing significantly to revenue.
  • CV Sciences plans to work with lawmakers to create a balanced regulatory environment for the hemp market.

Original source: Read original article

Frequently Asked Questions

CV Sciences reported revenues of $3.3 million for Q3 2025, a decline from $3.9 million in Q3 2024. Despite the drop, the company continues to diversify its product offerings, which may positively influence future revenue growth.
The gross margin for Q3 2025 was 48.5%, an improvement from 46.0% in Q3 2024, although it declined from 50.9% in Q2 2025. This suggests a stability in gross margins that could indicate efficient cost management.
CV Sciences recorded an adjusted EBITDA loss of $118,000 in Q3 2025, compared to a positive adjusted EBITDA of $59,000 in Q2 2025. Although it reflects challenges, ongoing product development efforts may enhance profitability in the future.
Sales volumes fell by 16% in Q3 2025, primarily due to out-of-stock issues and regulatory restrictions in some states. Addressing inventory challenges could foster a bounce back in sales.
While the recent funding legislation includes restrictive hemp language, CV Sciences plans to engage with lawmakers to shape a balanced regulatory framework. Their proactive approach may safeguard their market position.
CV Sciences launched 38 new products since January 2023, including the new Ignite men's performance formula. This expansion of the product line could attract new customers and drive future revenue.
As of Q3 2025, CV Sciences reported a cash balance of $0.4 million, down from $0.5 million at year-end 2024. Maintaining adequate liquidity is crucial for ongoing operations and new project investments.
Despite revenue declines, improvements in gross margins and strategic expansion efforts indicate a path toward recovery and potential growth. This could instil confidence amongst investors looking for long-term value.